Morten Mau‐Sørensen

Enhanced detection of circulating tumor DNA by fragment size analysis

Florent Moulière, Dineika Chandrananda, Anna Piskorz et al. · Science Translational Medicine · 2018 · 1K citations · Full text

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail et al. · Journal of Clinical Oncology · 2016 · 244 citations · Full text

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

Benedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen et al. · Neuro-Oncology · 2010 · 227 citations · Full text

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019 · 217 citations · Full text

Innovatv 201, Tisotumab Vedotin, Medicine +10

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

John Kuruvilla, Michael R. Savona, Rachid Baz et al. · Blood · 2017 · 156 citations · Full text